AbbVie faces questions about Skyrizi competition from J&Jnews2026-04-29T18:52:56+00:00April 29th, 2026|Endpoints News|
FDA, AstraZeneca prep for oncology adcommnews2026-04-29T18:32:20+00:00April 29th, 2026|Endpoints News|
Bristol Myers reaches a crossroads as a make-or-break year takes shapenews2026-04-29T15:33:16+00:00April 29th, 2026|Endpoints News|
AstraZeneca rekindles UK relationship, pledges £300M to expandnews2026-04-29T15:03:28+00:00April 29th, 2026|Endpoints News|
Chiesi signs $1.9B deal to acquire KalVista and its approved drugnews2026-04-29T13:25:38+00:00April 29th, 2026|Endpoints News|
GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readoutsnews2026-04-29T11:22:30+00:00April 29th, 2026|Endpoints News|
AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacynews2026-04-29T10:50:57+00:00April 29th, 2026|Endpoints News|
Pfizer delays patent cliff for blockbuster Vyndamaxnews2026-04-28T17:36:36+00:00April 28th, 2026|Endpoints News|
Hikma and Amarin’s generic drug case heads to Supreme Court argumentsnews2026-04-28T17:14:57+00:00April 28th, 2026|Endpoints News|
Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrelnews2026-04-28T13:20:17+00:00April 28th, 2026|Endpoints News|
